Amplia Therapeutics Share Price and Company Fundamentals
Last traded: Yesterday at 6:10 AM
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
Beta
-
Market cap
-
Enterprise value
-
Company profile
| Primary activities | Pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Website | https://www.ampliatx.com |
| Mailing address | 350 Queen Street Level 17 Melbourne VIC 3000 Australia |
| Phone / Fax | / |
| Share registry | COMPUTERSHARE INVESTOR SERVICES PTY LIMITED |
Dividends
Amplia Therapeutics does not pay dividends.
Company Executives
As of Aug 2022, following are the company executives and directors listed on Amplia Therapeutics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. John Lambert B.Sc., BSc (Hons), C.Chem., MRACI, Ph.D. | CEO, MD & Director | 56 | 355.02k |
| Mr. Hamish George | Chief Financial Officer | ||
| Ms. Rhiannon Jones B.Sc., Ph.D. | Chief Operating Officer | ||
| Mr. Andrew John Cooke FAICS, FCIS, FGIA, LLB, MAICD | Company Sec. | 61 | |
| Dr. Frank Gelder | Founding Scientist | ||
| Dr. James A. Taylor Ph.D. | Trials Consultant | 60 | |
| Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR | Trials Consultant | 73 | |
| Dr. Benjamin M. Segal | Clinical Consultant | ||
| Dr. Frederick E. Reno | Toxicology Consultant |
Profitability and management effectiveness
Profit margin
Operating margin
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Amplia Therapeutics is and its enterprise value is .
Companies similar to Amplia Therapeutics (ATX)
Amplia Therapeutics (ASX:ATX) Frequently Asked Questions
1. What is Amplia Therapeutics's Stock Symbol?
Amplia Therapeutics trades on ASX under the ticker symbol "ATX".
2. What is Amplia Therapeutics's stock price today?
One share of ATX stock can currently be purchased for approximately $0.1.
3. How can I contact Amplia Therapeutics?
Amplia Therapeutics's mailing address is 350 Queen Street Level 17 Melbourne VIC 3000 Australia. The company can be reached via phone at .
4. What is Amplia Therapeutics's official website?
The official website of Amplia Therapeutics is https://www.ampliatx.com.
5. Which share registry manages Amplia Therapeutics's stock?
Amplia Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.